The Janus face of dendritic cells in cancer

Oncogene

Volumn 27, Issue 45, 2008, Pages 5920-5931

  Chaput, N ^a,b,c   Conforti, R ^a,b,c   Viaud, S ^a,b   Spatz, A ^a,c   Zitvogel, L ^a,b,c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c IGR   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Dendritic cells; Tolerance; Tumor immunity

Indexed keywords

CYTOTOXIC AGENT; GLYCOLIPID;

ADOPTIVE TRANSFER; BLADDER; BONE MARROW CELL; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; COLORECTAL CANCER; DENDRITIC CELL; ENDOMETRIUM CARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GALLBLADDER CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; LARYNX CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MELANOMA; MOUTH CARCINOMA; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STOMACH CANCER; TONGUE CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; CYTOPROTECTION; DENDRITIC CELLS; DRUG THERAPY; HUMANS; IMMUNOLOGIC SURVEILLANCE; NEOPLASMS; TUMOR ESCAPE;

HARNESS;

EID: 53549126347     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.270     Document Type: Review

References (153)

1. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. (1998). Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4: 1321-1324.
2. Alli R, Savithri B, Das S, Varalakshmi C, Rangaraj N, Khar A. (2004). Involvement of NKR-P2/NKG2D in DC-mediated killing of tumor targets: indicative of a common, innate, target-recognition paradigm? Eur J Immunol 34: 1119-1126.
3. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED et al. (2000). Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766.
4. Ambe K, Mori M, Enjoji M. (1989). S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63: 496-503.
5. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J et al. (2004). Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 172: 2126-2136.
6. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
7. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D et al. (2007). Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204: 1037-1047.
8. Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G. (2003). Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 171: 6466-6477.
9. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A et al. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61: 6451-6458.
10. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S et al. (1999). In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190: 1417-1426.
11. Bellone G, Carbone A, Smirne C, Scirelli T, Buffolino A, Novarino A et al. (2006). Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 177: 3448-3460.
12. Bereta M, Bereta J, Park J, Medina F, Kwak H, Kaufman HL. (2004). Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles. Cancer Gene Ther 11: 808-818.
13. Blank C, Mackensen A. (2007). Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56: 739-745.
14. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. (2002). Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627-1638.
15. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C et al. (2004). Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388.
16. Bui JD, Schreiber RD. (2007). Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19: 203-208.
17. Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J et al. (2006). Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 132: 293-301.
18. Cao W, Rosen DB, Ito T, Bover L, Bao M, Watanabe G et al. (2006). Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 203: 1399-1405.
19. Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG, Finn OJ. (2005). Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 175: 1628-1635.
20. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701.
21. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. (1996). Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747-752.
22. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M et al. (2006). Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 12: 207-213.
23. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F et al. (2001). Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97: 3210-3217.
24. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P et al. (2004). Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172: 2137-2146.
25. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H et al. (2005). Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 102: 419-424.
26. Colonna M, Cella M. (2007). Crosspresentation: plasmacytoid dendritic cells are in the business. Immunity 27: 419-421.
27. Coventry BJ, Morton J. (2003). CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer 89: 533-538.
28. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A et al. (2003). Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89: 1463-1472.
29. Della Bella S, Nicola S, Brambilla L, Riva A, Ferrucci S, Presicce P et al. (2006). Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin Immunol 119: 317-329.
30. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
31. Drake CG, Jaffee E, Pardoll DM. (2006). Mechanisms of immune evasion by tumors. Adv Immunol 90: 51-81.
32. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543.
33. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J et al. (2007). IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 37: 1678-1690.
34. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S et al. (2007). Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111.
35. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
36. Dunn GP, Koebel CM, Schreiber RD. (2006). Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
37. Eisenthal A, Polyvkin N, Bramante-Schreiber L, Misonznik F, Hassner A, Lifschitz-Mercer B. (2001). Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 32: 803-807.
38. Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O et al. (2007). Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 13: 3825-3830.
39. Enk AH, Katz SI. (1992). Identification and induction of keratinocyte-derived IL-10. J Immunol 149: 92-95.
40. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. (1999). Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190: 1155-1164.
41. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. (2002). Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30receptor by activated NK cells. J Exp Med 195: 343-351.
42. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M et al. (1999). Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5: 405-411.
43. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. (2004). The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199: 1607-1618.
44. Furihata M, Ohtsuki Y, Ido E, Iwata J, Sonobe H, Araki K et al. (1992). HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma-their distribution in relation to prognosis. Virchows Arch B Cell Pathol Incl Mol Pathol 61: 409-414.
45. Furukawa T, Watanabe S, Sato Y, Kodama T, Nakajima T, Shimosato Y. (1984). Heterogeneity of histiocytes in primary lung cancer stained with anti-S100 protein, lysozyme and OKT 6 antibodies. Jpn J Clin Oncol 14: 647-657.
46. Furumoto K, Soares L, Engleman EG, Merad M. (2004). Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113: 774-783.
47. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
48. Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P et al. (2007). Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 125: 184-193.
49. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E et al. (2005). Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202: 919-929.
50. Gillessen S, Naumov YN, Nieuwenhuis EE, Exley MA, Lee FS, Mach N et al. (2003). CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA 100: 8874-8879.
51. Gilliet M, Liu YJ. (2002a). Generation of human CD8 T regulatory cells by CD40ligand-activa ted plasmacytoid dendritic cells. J Exp Med 195: 695-704.
52. Gilliet M, Liu YJ. (2002b). Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 63: 1149-1155.
53. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. (1998). Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124: 641-646.
54. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A et al. (2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3: 1097-1101.
55. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B et al. (2003). Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63: 6478-6487.
56. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. (2000). The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 165: 3730-3741.
57. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M et al. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089-1096.
58. Hoeffel G, Ripoche AC, Matheoud D, Nascimbeni M, Escriou N, Lebon P et al. (2007). Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 27: 481-492.
59. Honig A, Schaller N, Dietl J, Backe J, Kammerer U. (2005). S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Res 25: 1747-1753.
60. Ikarashi Y, Mikami R, Bendelac A, Terme M, Chaput N, Terada M et al. (2001). Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production. J Exp Med 194: 1179-1186.
61. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I et al. (2002). The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 8: 3480-3486.
62. Inoue K, Furihata M, Ohtsuki Y, Fujita Y. (1993). Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis. Virchows Arch A Pathol Anat Histopathol 422: 351-355.
63. Ishigami S, Aikou T, Natsugoe S, Hokita S, Iwashige H, Tokushige M et al. (1998). Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 55: 65-69.
64. Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Nakashima S et al. (2003). Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 10: 1237-1240.
65. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA et al. (2007). Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 204: 105-115.
66. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T et al. (2003). Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104: 92-97.
67. Josien R, Heslan M, Soulillou JP, Cuturi MC. (1997). Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J Exp Med 186: 467-472.
68. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G et al. (2004). Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene 331: 159-164.
69. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T et al. (2002). In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
70. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. (2005). Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 23: 611-620.
71. Kawamura K, Kadowaki N, Kitawaki T, Uchiyama T. (2006). Virus-stimulated plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T cells. Blood 107: 1031-1038.
72. Kissenpfennig A, Ait-Yahia S, Clair-Moninot V, Stossel H, Badell E, Bordat Y et al. (2005a). Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol Cell Biol 25: 88-99.
73. Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, Romani N et al. (2005b). Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22: 643-654.
74. Kissenpfennig A, Malissen B. (2006). Langerhans cells - revisiting the paradigm using genetically engineered mice. Trends Immunol 27: 132-139.
75. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. (2005). Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2: e284.
76. Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R et al. (2006). Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 203: 1859-1865.
77. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R et al. (2003). All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63: 4441-4449.
78. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A et al. (2007). Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56: 1459-1469.
79. Ladanyi A, Somlai B, Gilde K, Fejos Z, Gaudi I, Timar J. (2004). T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10: 521-530.
80. Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain Somerhausen N, Di Leo A et al. (1999). Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 84: 309-314.
81. Liu J, Xiang Z, Ma X. (2004). Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma. J Immunol 173: 1184-1193.
82. Liu YJ. (2005). IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23: 275-306.
83. Long EO. (2007). Ready for prime time: NK cell priming by dendritic cells. Immunity 26: 385-387.
84. Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T et al. (2005). An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol 174: 5298-5305.
85. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. (2007). Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26: 503-517.
86. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. (2000). Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 60: 3239-3246.
87. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD et al. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nat Med 1: 1297-1302.
88. McLellan AD, Sorg RV, Williams LA, Hart DN. (1996). Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway. Eur J Immunol 26: 1204-1210.
89. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C et al. (1998). Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791.
90. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al. (2006). All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66: 9299-9307.
91. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J et al. (2001). Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 194: 1013-1020.
92. Moretta A. (2002). Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2: 957-964.
93. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ et al. (2004). Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 173: 4433-4442.
94. Munn DH, Mellor AL, Rossi M, Young JW. (2005). Dendritic cells have the option to express IDO-mediated suppression or not. Blood 105: 2618.
95. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ et al. (2004). Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114: 280-290.
96. Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M et al. (2003). Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 89: 1736-1742.
97. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R et al. (2004). Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 172: 464-474.
98. O'Donnell RK, Mick R, Feldman M, Hino S, Wang Y, Brose MS et al. (2007). Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett 255: 145-152.
99. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
100. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.
101. Pashenkov M, Goess G, Wagner C, Hormann M, Jandl T, Moser A et al. (2006). Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24: 5716-5724.
102. Pereira CF, Torensma R, Hebeda K, Kretz-Rommel A, Faas SJ, Figdor CG et al. (2007). In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 30: 705-714.
103. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y et al. (2007). Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178: 2763-2769.
104. Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M. (2004). Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol 34: 66-73.
105. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. (2001). The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91: 2136-2147.
106. Riemann H, Loser K, Beissert S, Fujita M, Schwarz A, Schwarz T et al. (2005). IL-12 breaks dinitrothiocyanobenzene (DNTB)-mediated tolerance and converts the tolerogen DNTB into an immunogen. J Immunol 175: 5866-5874.
107. Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, de Saint Vis B et al. (2002). Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 100: 3295-3303.
108. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R et al. (1999). Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183-1186.
109. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R et al. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813.
110. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. (2007). Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13: 4565-4574.
111. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R et al. (2005). Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 11: 2576-2582.
112. Schmitz V, Dombrowski F, Prieto J, Qian C, Diehl L, Knolle P et al. (2006). Induction of murine liver damage by overexpression of CD40ligand provides an experimental model to study fulminant hepatic failure. Hepatology 44: 430-439.
113. Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C et al. (2005). Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465-2472.
114. Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J et al. (2004). Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood 103: 1391-1397.
115. Schnurr M, Toy T, Stoitzner P, Cameron P, Shin A, Beecroft T et al. (2003). ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood 102: 613-620.
116. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. (2007). Cross-presentation of glycolipid from tumor cells loaded with {alpha}-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 204: 2641-2653.
117. Simonetti O, Goteri G, Lucarini G, Rubini C, Stramazzotti D, Lo Muzio L et al. (2007). In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness:an immunohistochemical study. Int J Immunopathol Pharmacol 20: 325-333.
118. Smyth MJ, Dunn GP, Schreiber RD. (2006). Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50.
119. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S et al. (2003). Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21: 3343-3350.
120. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. (2007). Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90on dying tumor cells: therapeutic implications. Blood 109: 4839-4845.
121. Srivastava RM, Varalakshmi C, Khar A. (2007). Cross-linking a mAb to NKR-P2/NKG2D on dendritic cells induces their activation and maturation leading to enhanced anti-tumor immune response. Int Immunol 19: 591-607.
122. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. (2007). Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204: 1441-1451.
123. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. (1997). Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159: 4772-4780.
124. Steinman RM. (2007). Dendritic cells: versatile controllers of the immune system. Nat Med 13: 1155-1159.
125. Steinman RM, Banchereau J. (2007). Taking dendritic cells into medicine. Nature 449: 419-426.
126. Steinman RM, Hawiger D, Nussenzweig MC. (2003). Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711.
127. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203: 1651-1656.
128. Suzuki A, Masuda A, Nagata H, Kameoka S, Kikawada Y, Yamakawa M et al. (2002). Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 196: 37-43.
129. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP et al. (2005). Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106: 1278-1285.
130. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M et al. (2006a). A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12: 214-219.
131. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C et al. (2006b). Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176: 2722-2729.
132. Tang Q, Bluestone JA. (2006). Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol 7: 551-553.
133. Tang TJ, Vukosavljevic D, Janssen HL, Binda RS, Mancham S, Tilanus HW et al. (2006). Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol 37: 332-338.
134. Tepper RI, Mule JJ. (1994). Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5: 153-164.
135. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP et al. (2004). Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10: 7466-7474.
136. Trinite B, Chauvin C, Peche H, Voisine C, Heslan M, Josien R. (2005). Immature CD4- CD103+ rat dendritic cells induce rapid caspase-independent apoptosis-like cell death in various tumor and nontumor cells and phagocytose their victims. J Immunol 175: 2408-2417.
137. Trinite B, Voisine C, Yagita H, Josien R. (2000). A subset of cytolytic dendritic cells in rat. J Immunol 165: 4202-4208.
138. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. (1990). Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66: 2012-2016.
139. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T et al. (2007). Dendritic cell subsets in health and disease. Immunol Rev 219: 118-142.
140. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D et al. (2007). Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104: 8947-8952.
141. Villadangos JA, Schnorrer P. (2007). Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7: 543-555.
142. von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS et al. (2006). CD25 and indoleamine 2, 3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237.
143. Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N et al. (2005). Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 114: 52-60.
144. Yilmaz A, Reiss C, Weng A, Cicha I, Stumpf C, Steinkasserer A et al. (2006). Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 79: 529-538.
145. Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. (2003). Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 50: 1281-1284.
146. Yoneyama H, Matsuno K, Toda E, Nishiwaki T, Matsuo N, Nakano A et al. (2005). Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 202: 425-435.
147. Zhang J, Raper A, Sugita N, Hingorani R, Salio M, Palmowski MJ et al. (2006). Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107: 3600-3608.
148. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.
149. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ et al. (2005). Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 65: 1761-1769.
150. Zitvogel L. (2002). Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 195: F9-14.
151. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73.
152. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D et al. (1998). Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4: 594-600.
153. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T et al. (2001). Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7: 1339-1346.